Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
547 CERPASS: A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.